AbbVie completes acquisition of Cerevel Therapeutics
Michael Vi/iStock Editorial by way of Getty Photos AbbVie (NYSE:ABBV) has accomplished its ~$8.7B ($45 per share) acquisition of Cerevel ...
Sunday, May 4, 2025
Tag: Cerevel
RECOMMENDED
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.